Related references
Note: Only part of the references are listed.Paclitaxel-functionalized gold nanoparticles
Jacob D. Gibson et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Pulsed-high intensity focused ultrasound and low temperature sensitive liposomes for enhanced targeted drug delivery and antitumor effect
Sergio Dromi et al.
CLINICAL CANCER RESEARCH (2007)
Pharmacokinetics of poly(hydroxyethyl-L-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration
Birgit Romberg et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2007)
Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs
Shao-Qiong Liu et al.
BIOMATERIALS (2007)
Biomimetic amplification of nanoparticle homing to tumors
Dmitri Simberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Magnetic resonance imaging of temperature-sensitive liposome release: Drug dose painting and antitumor effects
Ana M. Ponce et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Encapsulation of paclitaxel in macromolecular nanoshells
Alisar S. Zahr et al.
BIOMACROMOLECULES (2007)
Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production
S. Moein Moghimi et al.
FASEB JOURNAL (2006)
Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity
A. Christy Hunter
ADVANCED DRUG DELIVERY REVIEWS (2006)
A bacterial protein enhances the release and efficacy of liposomal cancer drugs
Ian Cheong et al.
SCIENCE (2006)
Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes
Tatsuhiro Ishida et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin-encapsulation and high-dose first injection
Tatsuhiro Ishida et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Influence of formulation vehicle on metronomic taxane chemotherapy: Albumin-bound versus cremophor EL-based paclitaxel
Sylvia S. W. Ng et al.
CLINICAL CANCER RESEARCH (2006)
Polymer conjugates as anticancer nanomedicines
Ruth Duncan
NATURE REVIEWS CANCER (2006)
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
J Szebeni
TOXICOLOGY (2005)
Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue
TL Andresen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Low and high molecular weight poly(L-lysine)s/poly(L-lysine) - DNA complexes initiate mitochondrial-mediated apoptosis differently
P Symonds et al.
FEBS LETTERS (2005)
Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors
KM Laginha et al.
CLINICAL CANCER RESEARCH (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
A two-stage poly(ethylenimine)-mediated cytotoxicity: Implications for gene transfer/therapy
SM Moghimi et al.
MOLECULAR THERAPY (2005)
Nanomedicine: current status and future prospects
SM Moghimi et al.
FASEB JOURNAL (2005)
Recent advances with liposomes as pharmaceutical carriers
VP Torchilin
NATURE REVIEWS DRUG DISCOVERY (2005)
Block copolymer micelles as a solution for drug delivery problems
VP Torchilin
EXPERT OPINION ON THERAPEUTIC PATENTS (2005)
Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: Novel multicomponent delivery system
RI Pakunlu et al.
CANCER RESEARCH (2004)
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors:: an open-label, single-dose study
K Mross et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Causative factors behind poloxamer 188 (pluronic F68, Flocor™)-induced complement activation in human sera.: A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels
SM Moghimi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2004)
Negative preclinical results with stealth® nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model
I Brigger et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer
GJR Charrois et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2004)
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
LR Hirsch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin
CJ Provoda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions
A Chanan-Khan et al.
ANNALS OF ONCOLOGY (2003)
Multiple injections of pegylated liposomal doxorubicin: Pharmacokinetics and therapeutic activity
GJR Charrois et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Polymeric micelle for tumor pH and folate-mediated targeting
ES Lee et al.
JOURNAL OF CONTROLLED RELEASE (2003)
Aberrant vascular architecture in tumors and its importance in drug-based therapies
LL Munn
DRUG DISCOVERY TODAY (2003)
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer
CE Swenson et al.
ANTI-CANCER DRUGS (2003)
Accelerated clearance of PEGylated liposomes in rats after repeated injections
T Ishida et al.
JOURNAL OF CONTROLLED RELEASE (2003)
Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
A Gabizon et al.
CLINICAL PHARMACOKINETICS (2003)
Therapeutic synthetic polymers: a game of Russian roulette?
AC Hunter et al.
DRUG DISCOVERY TODAY (2002)
Ligand-targeted therapeutics in anticancer therapy
TM Allen
NATURE REVIEWS CANCER (2002)
Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs
B Ríhová et al.
JOURNAL OF CONTROLLED RELEASE (2002)
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
ES Kim et al.
LUNG CANCER (2001)
Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function
RK Jain
JOURNAL OF CONTROLLED RELEASE (2001)
Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers:: Pharmacokinetics and anti-tumor effects
YP Li et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2001)
Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors
A Pluen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions
J Szebeni et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2001)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
G Batist et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups
SM Moghimi et al.
PHARMACEUTICAL RESEARCH (2001)
Paclitaxel hypersensitivity reactions related to bee-sting allergy
E Grosen et al.
LANCET (2000)
Share Paper
